Proxy Votes Now

Home › Activist investors › Ra Capital Management, L.P.

Ra Capital Management, L.P.

Other large holder. Positions and campaigns from Ra Capital Management, L.P.’s SEC filings. Updated November 20, 2026.

Filer entities
RA CAPITAL MANAGEMENT, L.P.
SEC CIK
1346824 (RA CAPITAL MANAGEMENT, L.P.)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
Latest 13F
Quarter ended Sep 30, 2026, filed Nov 16, 2026: 91 US-listed positions reported; 56 of 1% or more of a company without a 13D are listed below.
78current positions
28new or changed in 90 days; 5 exited
0active campaigns
0campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (78)

CompanyStakeSourceFirst disclosedLast changeSince previous filingFlagsStated intent
Climb Bio, Inc. 33.0%23,941,277 shares Schedule 13D/A, filed Nov 9, 2026 Nov 17, 2023 Increased Nov 9, 2026 0.00 pts Increased Seeks changes or engagement
Pepgen Inc. 30.5%28,742,212 shares Schedule 13D/A, filed Nov 17, 2026 Feb 13, 2024 Increased Nov 17, 2026 ▲ 1.30 pts Increased —
Tyra Biosciences, Inc. 19.9%14,130,492 shares Schedule 13D/A, filed Sep 17, 2026 Feb 6, 2024 Increased Sep 17, 2026 ▼ 1.30 pts Increased Standard Item 4 language
Bambusa Therapeutics, Inc. 14.6%7,429,758 shares Schedule 13D, filed Nov 6, 2026 Nov 6, 2026 — — New Seeks changes or engagement
Sionna Therapeutics, Inc. 14.3%6,476,193 shares Schedule 13D/A, filed Sep 21, 2026 Feb 18, 2025 Decreased Sep 21, 2026 ▼ 8.30 pts Decreased Seeks changes or engagement
Corbus Pharmaceuticals Holdings, Inc. 9.90%1,914,788 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 4, 2026 Nov 16, 2026 — — New 13F: none stated
Scribe Therapeutics, Inc. 9.52%1,802,178 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 31, 2026 Nov 16, 2026 — — New 13F: none stated
Taysha Gene Therapies, Inc. 9.34%30,435,190 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 11, 2026 Nov 14, 2023 Increased Nov 16, 2026 ▲ 2.11 pts Increased 13F: none stated
Agenus Inc. 9.11%4,122,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 Nov 16, 2026 — — New 13F: none stated
Inovio Pharmaceuticals, Inc. 6.98%7,220,384 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 10, 2026 Nov 16, 2026 — — New 13F: none stated
C4 Therapeutics, Inc. 6.24%8,194,779 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 Feb 16, 2021 Increased Nov 16, 2026 ▼ 0.26 pts Increased 13F: none stated
Sagimet Biosciences Inc. 5.53%1,800,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 Nov 16, 2026 — — New 13F: none stated
Inhibikase Therapeutics, Inc. 5.28%6,970,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 1, 2026 Nov 16, 2026 — — New 13F: none stated
Capricor Therapeutics, Inc. 5.18%3,014,183 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 13, 2026 Feb 17, 2026 Increased Nov 16, 2026 ▲ 2.59 pts Increased 13F: none stated
JATT III Acquisition Corp 5.08%450,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 12, 2026 Nov 16, 2026 — — New 13F: none stated
Latigo Biotherapeutics, Inc. 4.20%5,302,933 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jun 30, 2026 Nov 16, 2026 — — New 13F: none stated
Damora Therapeutics, Inc. 3.88%2,399,702 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Nov 16, 2026 — — New 13F: none stated
Equillium, Inc. 3.66%2,317,741 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 7, 2026 May 15, 2026 Decreased Nov 16, 2026 ▼ 1.23 pts Decreased 13F: none stated
Amylyx Pharmaceuticals Inc. 3.33%4,279,341 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 Nov 16, 2026 — — New 13F: none stated
Jade Biosciences, Inc. 2.89%1,835,542 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 3, 2026 Aug 16, 2021 Decreased Nov 16, 2026 ▼ 2.89 pts Decreased 13F: none stated
Ovid Therapeutics Inc. 2.87%5,598,200 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 11, 2026 Aug 14, 2020 Decreased Nov 16, 2026 ▼ 2.51 pts Decreased 13F: none stated
Entera Bio Ltd. 2.81%4,901,960 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Nov 16, 2026 — — New 13F: none stated
Electra Therapeutics, Inc. 2.69%1,692,965 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 6, 2026 Nov 16, 2026 — — New 13F: none stated
Anteris Technologies Global Corp. 2.54%2,474,076 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 10, 2026 May 15, 2026 Decreased Nov 16, 2026 ▼ 0.54 pts Decreased 13F: none stated
Cyclerion Therapeutics, Inc. 1.96%892,743 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Nov 16, 2026 — — New 13F: none stated
Sutro Biopharma, Inc. 1.27%210,934 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 7, 2026 Nov 16, 2026 — — New 13F: none stated
DBV Technologies 1.16%3,657,644 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 Nov 16, 2026 — — New 13F: none stated
Artiva Biotherapeutics, Inc. 37.9%18,415,956 shares Schedule 13D/A, filed Jul 23, 2026 Jul 29, 2024 Increased Jul 23, 2026 ▲ 1.30 pts — Seeks changes or engagement
Acumen Pharmaceuticals, Inc. 29.5%21,101,669 shares Schedule 13D/A, filed Mar 17, 2026 Jul 25, 2023 Increased Mar 17, 2026 ▲ 4.70 pts — Seeks changes or engagement
Acrivon Therapeutics, Inc. 28.8%12,284,906 shares Schedule 13D/A, filed Apr 23, 2026 Apr 11, 2024 Increased Apr 23, 2026 ▲ 7.20 pts — Standard Item 4 language
Spyglass Pharma, Inc. 24.1%8,022,639 shares Schedule 13D, filed Feb 17, 2026 Feb 17, 2026 — — — Seeks changes or engagement
Parabilis Medicines, Inc. 23.8%28,933,371 shares Schedule 13D, filed Jun 18, 2026 Jun 18, 2026 — — — Seeks changes or engagement
Vor Biopharma Inc. 19.9%12,937,855 shares Schedule 13D/A, filed Jul 21, 2026 Aug 11, 2023 Increased Jul 21, 2026 0.00 pts — Standard Item 4 language
Janux Therapeutics, Inc. 19.9%11,971,377 shares Schedule 13D/A, filed Mar 10, 2025 Mar 6, 2024 Increased Mar 10, 2025 ▼ 0.09 pts — Standard Item 4 language
Nkarta, Inc. 18.9%13,848,371 shares Schedule 13D/A, filed Mar 29, 2024 Mar 29, 2024 — — — Standard Item 4 language
Wave Life Sciences, Inc. 16.8%34,314,406 shares Schedule 13D/A, filed Aug 11, 2026 Oct 1, 2024 Increased Mar 30, 2026 ▼ 0.30 pts — Standard Item 4 language
Hemab Therapeutics Holdings, Inc. 16.72%7,808,627 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 Aug 14, 2026 — 0.00 pts — 13F: none stated
Freenome, Inc. 14.3%15,367,270 shares Schedule 13D/A, filed Jul 22, 2026 Dec 12, 2025 — ▲ 5.90 pts — Seeks changes or engagement
Septerna, Inc. 11.8%5,525,324 shares Schedule 13D/A, filed Aug 14, 2026 Nov 4, 2024 Decreased Aug 14, 2026 ▼ 4.00 pts — Seeks changes or engagement
Bicara Therapeutics Inc. 11.5%7,279,739 shares Schedule 13D/A, filed Mar 2, 2026 Sep 23, 2024 Increased Mar 2, 2026 ▼ 1.30 pts — Seeks changes or engagement
Ars Pharmaceuticals, Inc. 11.1%10,940,977 shares Schedule 13D/A, filed Oct 1, 2025 Aug 31, 2023 Increased Oct 1, 2025 ▼ 0.20 pts — Standard Item 4 language
Solid Biosciences Inc. 10.8%12,036,126 shares Schedule 13D/A, filed Nov 6, 2026 Jan 11, 2024 Increased Jun 24, 2026 ▼ 1.10 pts — Standard Item 4 language
Adicet Bio, Inc. 9.96%932,624 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 Nov 14, 2022 — 0.00 pts — 13F: none stated
Monopar Therapeutics Inc. 9.96%667,207 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Apr 30, 2026 Feb 14, 2025 — 0.00 pts — 13F: none stated
Mineralys Therapeutics, Inc. 9.9%7,796,433 shares Schedule 13D/A, filed Sep 8, 2025 Feb 12, 2024 Increased Sep 8, 2025 0.00 pts — Standard Item 4 language
SAB Biotherapeutics, Inc. 9.9%9,609,852 shares Schedule 13D/A, filed Aug 10, 2026 Oct 3, 2025 Increased Aug 10, 2026 0.00 pts — Standard Item 4 language
OnKure Therapeutics, Inc. 9.87%3,998,333 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 May 15, 2026 — 0.00 pts — 13F: none stated
Century Therapeutics, Inc. 9.80%17,754,430 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 3, 2026 Aug 16, 2021 — 0.00 pts — 13F: none stated
Rezolute, Inc. 9.77%9,445,039 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Sep 21, 2026 Feb 17, 2026 — ▼ 0.04 pts — 13F: none stated
4D Molecular Therapeutics, Inc. 9.66%5,049,779 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 Aug 14, 2023 — 0.00 pts — 13F: none stated
Rhythm Pharmaceuticals, Inc. 9.62%6,666,837 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Aug 14, 2018 — ▼ 0.07 pts — 13F: none stated
ALX Oncology Holdings Inc. 9.41%13,011,849 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 30, 2026 May 15, 2026 — 0.00 pts — 13F: none stated
Evommune, Inc. 8.5%3,494,638 shares Schedule 13D/A, filed Nov 10, 2026 Nov 17, 2025 Increased Feb 17, 2026 ▼ 1.20 pts — Seeks changes or engagement
NewAmsterdam Pharma Company N.V. 8.24%9,883,524 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Feb 14, 2023 — ▼ 0.03 pts — 13F: none stated
Prelude Therapeutics Incorporated 8.13%6,475,882 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 7, 2026 Aug 14, 2026 — 0.00 pts — 13F: none stated
Aclaris Therapeutics, Inc. 8.02%12,723,026 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 Feb 16, 2016 — ▼ 0.62 pts — 13F: none stated
Q32 Bio Inc. 7.79%2,332,457 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 31, 2026 Aug 14, 2026 — ▼ 0.04 pts — 13F: none stated
Edgewise Therapeutics, Inc. 7.67%8,392,730 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 31, 2026 May 17, 2021 — ▼ 0.06 pts — 13F: none stated
Vaxcyte, Inc. 7.25%11,474,599 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Aug 14, 2020 — ▼ 0.46 pts — 13F: none stated
Xencor, Inc. 7.03%5,274,274 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 May 15, 2014 — ▼ 0.06 pts — 13F: none stated
LB Pharmaceuticals Inc 6.82%2,208,604 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 Nov 14, 2025 — ▼ 0.02 pts — 13F: none stated
Sana Biotechnology, Inc. 6.74%18,750,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Apr 30, 2026 Aug 14, 2026 — 0.00 pts — 13F: none stated
Geron Corporation 6.64%42,754,145 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 Aug 14, 2020 — ▼ 0.03 pts — 13F: none stated
JATT II Acquisition Corp. 6.41%500,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 12, 2026 Aug 14, 2026 — ▲ 0.18 pts — 13F: none stated
Lexeo Therapeutics, Inc. 6.37%5,000,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 7, 2026 May 15, 2024 — 0.00 pts — 13F: none stated
Editas Medicine Inc. 5.79%8,889,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 Aug 14, 2026 — 0.00 pts — 13F: none stated
Disc Medicine, Inc. 5.38%2,450,221 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 29, 2026 May 15, 2025 — ▼ 1.00 pts — 13F: none stated
Benitec Biopharma Inc. 5.30%1,850,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Sep 4, 2026 Feb 17, 2026 — ▼ 0.08 pts — 13F: none stated
Assembly Biosciences, Inc. 5.01%1,020,410 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 7, 2026 Nov 14, 2025 — 0.00 pts — 13F: none stated
Rani Therapeutics Holdings, Inc. 4.72%8,500,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 Feb 17, 2026 — 0.00 pts — 13F: none stated
Palisade Bio, Inc. 4.10%7,124,116 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 7, 2026 Feb 17, 2026 — 0.00 pts — 13F: none stated
Palatin Technologies, Inc. 3.49%62,124 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Sep 25, 2026 Feb 17, 2026 — 0.00 pts — 13F: none stated
Altimmune Inc. 3.34%6,500,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 7, 2026 Aug 14, 2026 — 0.00 pts — 13F: none stated
MacroGenics, Inc. 2.93%1,864,176 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 8, 2026 May 15, 2014 — 0.00 pts — 13F: none stated
Aura Biosciences, Inc. 2.41%2,500,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 6, 2026 Aug 14, 2026 — 0.00 pts — 13F: none stated
Oruka Therapeutics, Inc. 2.35%1,554,597 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 Aug 14, 2026 — 0.00 pts — 13F: none stated
Avalo Therapeutics, Inc. 1.73%1,000,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Nov 14, 2024 — ▼ 0.14 pts — 13F: none stated
Seaport Therapeutics, Inc. 1.31%700,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 Aug 14, 2026 — 0.00 pts — 13F: none stated

Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.

Stated intent (13D Item 4)

Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.

Climb Bio, Inc. · Seeks changes or engagement

“Item 4 of the Statement is hereby amended and supplemented as follows: On June 29, 2026 Dr. Breanna Celebi (O'Reilly), an Analyst of RA Capital, was appointed to the Board of Directors of the Issuer as the designee of RA Capital, replacing Dr. Andrew Levin, who resigned from the Board of Directors effective June 29, 2026.”

Item 4 in the Schedule 13D/A filed Nov 9, 2026; this amendment did not restate Item 4, so the text is from the filing of Jul 7, 2026.

Tyra Biosciences, Inc. · Standard Item 4 language

Item 4 in the Schedule 13D/A filed Sep 17, 2026.

Bambusa Therapeutics, Inc. · Seeks changes or engagement

“The Reporting Persons acquired the common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. The Reporting Persons may, from time to time, acquire additional equity securities or debt securities of the Issuer, which debt securities may be convertible or non-convertible, secured or unsecured, and could involve the monetization of potential revenue streams deriving…”

Item 4 in the Schedule 13D filed Nov 6, 2026.

Summary of the filing RA Capital reports a 14.6% post-IPO stake in Bambusa Therapeutics acquired for investment purposes, with a partner continuing to serve as a company director.

Quoted from the filing (item 4): “Dr. Derek DiRocco, a Partner of RA Capital, currently serves as a director of the Issuer and therefore will engage in regular discussions with the Issuer's board of directors and management as part of his duties as a director.” Nov 6, 2026

Sionna Therapeutics, Inc. · Seeks changes or engagement

“The Reporting Persons acquired the Common Stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time, acquire additional equity securities or debt securities…”

Item 4 in the Schedule 13D/A filed Sep 21, 2026; this amendment did not restate Item 4, so the text is from the filing of Feb 18, 2025.

Artiva Biotherapeutics, Inc. · Seeks changes or engagement

“The Reporting Persons acquired the Common Stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may acquire additional Issuer securities from time to time or dispose of”

Item 4 in the Schedule 13D/A filed Jul 23, 2026; this amendment did not restate Item 4, so the text is from the filing of Jul 29, 2024.

Acumen Pharmaceuticals, Inc. · Seeks changes or engagement

“The Reporting Persons acquired the Common Stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may acquire additional Issuer securities from time to time or dispose of…”

Item 4 in the Schedule 13D/A filed Mar 17, 2026; this amendment did not restate Item 4, so the text is from the filing of Jul 25, 2023.

Acrivon Therapeutics, Inc. · Standard Item 4 language

Item 4 in the Schedule 13D/A filed Apr 23, 2026.

Spyglass Pharma, Inc. · Seeks changes or engagement

“The Reporting Persons acquired the common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time, acquire additional equity securities or debt securities…”

Item 4 in the Schedule 13D filed Feb 17, 2026.

Parabilis Medicines, Inc. · Seeks changes or engagement

“The Reporting Persons acquired the voting common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. The Reporting Persons may, from time to time, acquire additional equity securities or debt securities of the Issuer, which debt securities may be convertible or non-convertible, secured or unsecured, and could involve the monetization of potential revenue streams deriving…”

Item 4 in the Schedule 13D filed Jun 18, 2026.

Vor Biopharma Inc. · Standard Item 4 language

“Item 4 of the Statement is hereby amended and supplemented as follows: Effective July 6, 2026, Andrew Levin resigned from the Board of Directors of the Issuer.”

Item 4 in the Schedule 13D/A filed Jul 21, 2026.

Janux Therapeutics, Inc. · Standard Item 4 language

“Item 4 of the Statement is hereby amended and supplemented as follows: The information in Item 6 is incorporated herein. At 11:59 pm on October 15, 2024, pursuant to the Stock Purchase Agreement, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired. All closing conditions were satisfied, and the transactions contemplated by the Stock Purchase Agreement…”

Item 4 in the Schedule 13D/A filed Mar 10, 2025; this amendment did not restate Item 4, so the text is from the filing of Oct 22, 2024.

Nkarta, Inc. · Standard Item 4 language

Item 4 in the Schedule 13D/A filed Mar 29, 2024.

Wave Life Sciences, Inc. · Standard Item 4 language

“Item 4 of the Statement is hereby amended and supplemented as follows: On August 7, 2026, as part of the Redomiciliation, Wave-Delaware, became the ultimate parent company of the Wave Life Sciences group of companies. Pursuant to the Scheme of Arrangement, all issued ordinary shares in the capital of Wave Life Sciences Ltd. ("Wave-Singapore") as of immediately prior to the effective time of the Scheme…”

Item 4 in the Schedule 13D/A filed Aug 11, 2026.

Summary of the filing RA Capital's 13D/A reports completion of Wave Life Sciences' Delaware redomiciliation, with Wave-Singapore shares exchanged one-for-one for new Wave-Delaware common stock, and no campaign-specific plans.

Quoted from the filing (item 4): “all issued ordinary shares in the capital of Wave Life Sciences Ltd. ("Wave-Singapore") as of immediately prior to the effective time of the Scheme of Arrangement were exchanged on a one-for-one basis for newly issued shares of common stock” Aug 11, 2026

Freenome, Inc. · Seeks changes or engagement

“The Reporting Persons acquired the common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. The Reporting Persons may, from time to time, acquire additional equity securities or debt securities of the Issuer, which debt securities may be convertible or non-convertible, secured or unsecured, and could involve the monetization of potential revenue streams deriving…”

Item 4 in the Schedule 13D/A filed Jul 22, 2026.

Septerna, Inc. · Seeks changes or engagement

“The Reporting Persons acquired the Common Stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time, acquire additional equity securities or debt securities…”

Item 4 in the Schedule 13D/A filed Aug 14, 2026; this amendment did not restate Item 4, so the text is from the filing of Nov 4, 2024.

Bicara Therapeutics Inc. · Seeks changes or engagement

“The Reporting Persons acquired the Common Stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time, acquire additional equity securities or debt securities…”

Item 4 in the Schedule 13D/A filed Mar 2, 2026; this amendment did not restate Item 4, so the text is from the filing of Sep 23, 2024.

Ars Pharmaceuticals, Inc. · Standard Item 4 language

“Item 4 is hereby amended and supplemented as follows: On September 29, 2025, the Issuer and certain direct and indirect subsidiaries of the Issuer who may become a party thereto from time to time, as guarantors (the "Guarantors"), and ARS Pharmaceuticals Operations, Inc., a wholly owned subsidiary of the Issuer, as the borrower (the "Borrower" and, collectively with the Guarantors, the "Credit Parties…”

Item 4 in the Schedule 13D/A filed Oct 1, 2025.

Mineralys Therapeutics, Inc. · Standard Item 4 language

Item 4 in the Schedule 13D/A filed Sep 8, 2025.

SAB Biotherapeutics, Inc. · Standard Item 4 language

“Item 4 of the Statement is hereby amended and supplemented as follows: Pursuant to the Letter Agreement, RA Capital recommended David Zaccardelli, Pharm.D, and Rita Jain, M.D. to serve as directors of the Issuer. On January 5, 2026, the Board of Directors (the "Board") of the Issuer, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Drs. Zaccardelli…”

Item 4 in the Schedule 13D/A filed Aug 10, 2026; this amendment did not restate Item 4, so the text is from the filing of Mar 11, 2026.

Evommune, Inc. · Seeks changes or engagement

“The Reporting Persons acquired the common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time, acquire additional equity securities or debt securities…”

Item 4 in the Schedule 13D/A filed Nov 10, 2026; this amendment did not restate Item 4, so the text is from the filing of Nov 17, 2025.

Past positions (16)
CompanyLast stakeSourceOutcomeDate
Biocryst Pharmaceuticals Inc. 6.19% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 31, 2026 Not in the latest 13F Nov 16, 2026
BioAge Labs, Inc. 3.64% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 31, 2026 Not in the latest 13F Nov 16, 2026
Definium Therapeutics, Inc. 1.38% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Apr 30, 2026 Not in the latest 13F Nov 16, 2026
Intellia Therapeutics Inc, 3.23% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 31, 2026 Not in the latest 13F Nov 16, 2026
Karyopharm Therapeutics Inc. 8.45% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Aug 6, 2026 Not in the latest 13F Nov 16, 2026
Lenz Therapeutics, Inc. 0.2% Schedule 13D/A, filed Nov 2, 2026 Reported below 5% in a 13D/A Nov 2, 2026
Werewolf Therapeutics, Inc. 4.1% Schedule 13D/A, filed Jul 2, 2026 Reported below 5% in a 13D/A Jul 2, 2026
Cidara Therapeutics, Inc. 0.0% Schedule 13D/A, filed Jan 9, 2026 Exited Jan 9, 2026
89BIO, Inc. 0.0% Schedule 13D/A, filed Nov 3, 2025 Exited Nov 3, 2025
Iteos Therapeutics, Inc. 4.9% Schedule 13D/A, filed May 19, 2025 Reported below 5% in a 13D/A May 19, 2025
Black Diamond Therapeutics, Inc. 5.0% Schedule 13D/A, filed May 9, 2024 Reported below 5% in a 13D/A May 9, 2024
Connect Biopharma Holdings Ltd 0.0% Schedule 13D/A, filed Feb 27, 2024 Exited Feb 27, 2024
Icosavax, Inc. 0.0% Schedule 13D/A, filed Feb 21, 2024 Exited Feb 21, 2024
Cytek Biosciences, Inc. 5.0% Schedule 13D/A, filed Sep 19, 2023 Reported below 5% in a 13D/A Sep 19, 2023
DICE Therapeutics, Inc. 0.0% Schedule 13D/A, filed Aug 9, 2023 Exited Aug 9, 2023
Satsuma Pharmaceuticals, Inc. 0.0% Schedule 13D/A, filed Jun 12, 2023 Exited Jun 12, 2023

Other disclosed holders around the same time

Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Ra Capital Management, L.P.’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.

Scribe Therapeutics, Inc. · Ra Capital Management, L.P. first disclosed Nov 16, 2026 · 3 other filings
HolderFormDateStake
Orbimed Advisors LLC Schedule 13D Jul 29, 2026 7.2%
ELI LILLY & Co Schedule 13D Jul 30, 2026 7.3%
Avoro Capital Advisors LLC Schedule 13D Jul 30, 2026 16.4%
Inovio Pharmaceuticals, Inc. · Ra Capital Management, L.P. first disclosed Nov 16, 2026 · 4 other filings
HolderFormDateStake
Vanguard Capital Management Schedule 13G Jul 31, 2026 5.0%
FMR LLC Schedule 13G Aug 6, 2026 10.3%
RA Capital Management, L.P. Schedule 13G Aug 7, 2026 9.9%
Adage Capital Management, L.P. Schedule 13G Aug 12, 2026 4.0%
Entera Bio Ltd. · Ra Capital Management, L.P. first disclosed Nov 16, 2026 · 2 other filings
HolderFormDateStake
Biotechnology Value Fund L P Schedule 13D Aug 4, 2026 10.0%
Nantahala Capital 13F Nov 13, 2026 1.7%
Sagimet Biosciences Inc. · Ra Capital Management, L.P. first disclosed Nov 16, 2026 · 2 other filings
HolderFormDateStake
Caligan Partners 13F Aug 14, 2026 8.6%
Nantahala Capital 13F Nov 13, 2026 1.4%
Latigo Biotherapeutics, Inc. · Ra Capital Management, L.P. first disclosed Nov 16, 2026 · 1 other filing
HolderFormDateStake
Foresite Capital Fund VI LP Schedule 13D Aug 17, 2026 14.5%
JATT III Acquisition Corp · Ra Capital Management, L.P. first disclosed Nov 16, 2026 · 2 other filings
HolderFormDateStake
JATT Ventures III L.P. Schedule 13D Sep 3, 2026 22.1%
Nantahala Capital 13F Nov 13, 2026 2.8%
Cyclerion Therapeutics, Inc. · Ra Capital Management, L.P. first disclosed Nov 16, 2026 · 2 other filings
HolderFormDateStake
Fairmount Funds Management LLC Schedule 13D Sep 11, 2026 20.0%
Venrock Healthcare Capital Partners III, L.P. Schedule 13D Sep 15, 2026 9.9%
Electra Therapeutics, Inc. · Ra Capital Management, L.P. first disclosed Nov 16, 2026 · 1 other filing
HolderFormDateStake
Orbimed Advisors LLC Schedule 13D Sep 25, 2026 11.0%
Oruka Therapeutics, Inc. · Ra Capital Management, L.P. first disclosed Aug 14, 2026 · 4 other filings
HolderFormDateStake
RTW Investments, LP Schedule 13G Feb 17, 2026 4.3%
Viking Global Investors LP Schedule 13G May 15, 2026 5.3%
Capital World Investors Schedule 13G Aug 12, 2026 5.6%
Venrock Healthcare Capital Partners III, L.P. Schedule 13G Aug 14, 2026 7.4%
Altimmune Inc. · Ra Capital Management, L.P. first disclosed Aug 14, 2026 · 6 other filings
HolderFormDateStake
Deep Track Capital, LP Schedule 13G Apr 30, 2026 10.0%
Viking Global Investors LP Schedule 13G May 1, 2026 6.7%
Chen Yu Schedule 13G May 1, 2026 9.8%
RA Capital Management, L.P. Schedule 13G May 1, 2026 6.5%
State Street Corporation Schedule 13G May 12, 2026 5.5%
Tang Capital Management, LLC Schedule 13G May 15, 2026 0.3%
Seaport Therapeutics, Inc. · Ra Capital Management, L.P. first disclosed Aug 14, 2026 · 2 other filings
HolderFormDateStake
ARCH Venture Fund XII, L.P. Schedule 13D May 6, 2026 11.9%
General Atlantic, L.P. Schedule 13D May 11, 2026 11.5%
Hemab Therapeutics Holdings, Inc. · Ra Capital Management, L.P. first disclosed Aug 14, 2026 · 1 other filing
HolderFormDateStake
AI Den-Mab LLC Schedule 13D May 11, 2026 10.4%
Editas Medicine Inc. · Ra Capital Management, L.P. first disclosed Aug 14, 2026 · 5 other filings
HolderFormDateStake
Commodore Capital LP Schedule 13G Jun 2, 2026 9.9%
TCG Crossover GP III, LLC Schedule 13G Jun 3, 2026 9.9%
RA Capital Management, L.P. Schedule 13G Jun 3, 2026 5.8%
BlackRock, Inc. Schedule 13G Jul 29, 2026 5.0%
ADAR1 Capital Management, LLC Schedule 13G Aug 14, 2026 5.8%
JATT II Acquisition Corp. · Ra Capital Management, L.P. first disclosed Aug 14, 2026 · 2 other filings
HolderFormDateStake
Nantahala Capital 13F Aug 14, 2026 2.9%
JATT Ventures II L.P. Schedule 13D Sep 15, 2026 23.1%
Anteris Technologies Global Corp. · Ra Capital Management, L.P. first disclosed May 15, 2026 · 1 other filing
HolderFormDateStake
Medtronic plc Schedule 13D Jan 29, 2026 16.2%
OnKure Therapeutics, Inc. · Ra Capital Management, L.P. first disclosed May 15, 2026 · 1 other filing
HolderFormDateStake
AI Biotechnology LLC Schedule 13D Apr 7, 2026 20.0%
ALX Oncology Holdings Inc. · Ra Capital Management, L.P. first disclosed May 15, 2026 · 1 other filing
HolderFormDateStake
Nantahala Capital 13F Aug 14, 2026 1.1%
Capricor Therapeutics, Inc. · Ra Capital Management, L.P. first disclosed Feb 17, 2026 · 6 other filings
HolderFormDateStake
The Vanguard Group Schedule 13G Oct 30, 2025 4.8%
Tang Capital Management, LLC Schedule 13G Jan 26, 2026 6.6%
Highbridge Capital Management, LLC Schedule 13G Feb 17, 2026 2.3%
Suvretta Capital Management, LLC Schedule 13G Feb 26, 2026 6.6%
RA Capital Management, L.P. Schedule 13G Aug 3, 2026 5.2%
State Street Corporation Schedule 13G Aug 7, 2026 5.9%
Rani Therapeutics Holdings, Inc. · Ra Capital Management, L.P. first disclosed Feb 17, 2026 · 1 other filing
HolderFormDateStake
Samsara BioCapital, L.P. Schedule 13D Oct 30, 2025 9.9%
Rezolute, Inc. · Ra Capital Management, L.P. first disclosed Feb 17, 2026 · 6 other filings
HolderFormDateStake
FMR LLC Schedule 13G Jan 8, 2026 2.5%
The Vanguard Group Schedule 13G Jan 30, 2026 5.2%
Bank of America Corp /De/ Schedule 13G Feb 11, 2026 6.5%
Opaleye Management Inc. Schedule 13G May 11, 2026 6.6%
Balyasny Asset Management L.P. Schedule 13G May 15, 2026 5.3%
Dellora Investments LP Schedule 13G Aug 12, 2026 5.9%
Spyglass Pharma, Inc. · Ra Capital Management, L.P. first disclosed Feb 17, 2026 · 3 other filings
HolderFormDateStake
Vensana Capital I GP, LLC Schedule 13D Feb 10, 2026 9.9%
New Enterprise Associates 17, L.P. Schedule 13D Feb 13, 2026 22.2%
Gilde Healthcare Holding B.V. Schedule 13D Feb 13, 2026 6.6%
Evommune, Inc. · Ra Capital Management, L.P. first disclosed Nov 17, 2025 · 1 other filing
HolderFormDateStake
LSP 7 Cooperatieve U.A. Schedule 13D Nov 14, 2025 15.7%
LB Pharmaceuticals Inc · Ra Capital Management, L.P. first disclosed Nov 14, 2025 · 3 other filings
HolderFormDateStake
Deep Track Biotechnology Master Fund, Ltd. Schedule 13D Sep 19, 2025 14.9%
Pontifax Management 4 G.P. (2015) Ltd. Schedule 13D Sep 25, 2025 6.3%
Nantahala Capital 13F Nov 14, 2025 3.3%
Disc Medicine, Inc. · Ra Capital Management, L.P. first disclosed May 15, 2025 · 5 other filings
HolderFormDateStake
Wellington Management Group LLP Schedule 13G Feb 10, 2025 4.7%
FMR LLC Schedule 13G Feb 12, 2025 6.3%
Bain Capital Life Sciences Opportunities III, LP Schedule 13G Feb 14, 2025 3.3%
Paradigm BioCapital Advisors LP Schedule 13G May 15, 2025 3.5%
Frazier Life Sciences Public Fund, L.P. Schedule 13G Aug 14, 2025 3.0%
Sionna Therapeutics, Inc. · Ra Capital Management, L.P. first disclosed Feb 18, 2025 · 4 other filings
HolderFormDateStake
Orbimed Advisors LLC Schedule 13D Feb 13, 2025 8.4%
Enavate Sciences GP, LLC Schedule 13D Feb 18, 2025 5.6%
Atlas Venture Fund XI, L.P. Schedule 13D Feb 18, 2025 6.5%
TPG GP a, LLC Schedule 13D Feb 18, 2025 15.2%
BioAge Labs, Inc. · Ra Capital Management, L.P. first disclosed Nov 14, 2024 · 2 other filings
HolderFormDateStake
Sofinnova Venture Partners XI, L.P. Schedule 13D Sep 30, 2024 6.7%
AH Bio Fund I, L.P. Schedule 13D Oct 4, 2024 9.0%
Wave Life Sciences, Inc. · Ra Capital Management, L.P. first disclosed Oct 1, 2024 · 2 other filings
HolderFormDateStake
BlackRock, Inc. Schedule 13G Feb 5, 2025 6.1%
Maverick Capital, Ltd. Schedule 13G Feb 14, 2025 5.4%
Bicara Therapeutics Inc. · Ra Capital Management, L.P. first disclosed Sep 23, 2024 · 1 other filing
HolderFormDateStake
TPG GP a, LLC Schedule 13D Sep 18, 2024 5.5%
Artiva Biotherapeutics, Inc. · Ra Capital Management, L.P. first disclosed Jul 29, 2024 · 1 other filing
HolderFormDateStake
GC Corp. Schedule 13D Jul 29, 2024 19.6%
Lenz Therapeutics, Inc. · Ra Capital Management, L.P. first disclosed Mar 28, 2024 · 1 other filing
HolderFormDateStake
Tang Capital 13F May 15, 2024 1.4%
Connect Biopharma Holdings Ltd · Ra Capital Management, L.P. first disclosed Dec 4, 2023 · 1 other filing
HolderFormDateStake
Panacea Innovation Ltd Schedule 13D Feb 13, 2024 16.2%
NewAmsterdam Pharma Company N.V. · Ra Capital Management, L.P. first disclosed Feb 14, 2023 · 1 other filing
HolderFormDateStake
Forbion Capital Fund IV Cooperatief U.A. Schedule 13D Jul 7, 2023 10.1%

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.